Adaptive capacity of the right ventricle: Why does it fail?

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 308, Issue 8, 2015, Pages H803-H813

  Poels, Ella M ^a,b   da Costa Martins, Paula A ^a   van Empel, Vanessa P M ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Heart failure; Molecular; Pulmonary hypertension; Right ventricle; Right ventricular failure

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NEUROHORMONE; VASODILATOR AGENT;

APOPTOSIS; EXERCISE TOLERANCE; HEART LEFT VENTRICLE FUNCTION; HEART OUTPUT; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL; ADAPTATION; ANIMAL; HYPERTROPHY, RIGHT VENTRICULAR; METABOLISM; PATHOPHYSIOLOGY;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; HUMANS; HYPERTROPHY, RIGHT VENTRICULAR; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 84927941927     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00573.2014     Document Type: Review

References (146)

1. Aguero J, Ishikawa K, Hadri L, Santos-Gallego CG, Fish K, Hammoudi N, Chaanine AH, Torquato S, Naim C, Ibanez B, Pereda D, Garcia-Alvarez A, Fuster V, Sengupta PP, Leopold JA, Hajjar RJ. Characterization of right ventricular remodeling and failure in a chronic pulmonary hypertension model. Am J Physiol Heart Circ Physiol 307: H1204-H1215, 2014.
2. Anker SD, Egerer KR, Volk HD, Kox WJ, Poole-Wilson PA, Coats AJ. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol 79: 1426-1430, 1997.
3. Aronson D, Darawsha W, Atamna A, Kaplan M, Makhoul BF, Mutlak D, Lessick J, Carasso S, Reisner S, Agmon Y, Dragu R, Azzam ZS. Pulmonary hypertension, right ventricular function, and clinical outcome in acute decompensated heart failure. J Card Fail 19: 665-671, 2013.
4. Bartelds B, Borgdorff MA, Smit-van Oosten A, Takens J, Boersma B, Nederhoff MG, Elzenga NJ, van Gilst WH, De Windt LJ, Berger RM. Differential responses of the right ventricle to abnormal loading conditions in mice: pressure vs. volume load. Eur J Heart Fail 13: 1275-1282, 2011.
5. Blais C Jr, Marceau F, Rouleau JL, Adam A. The kallikrein-kininogen- kinin system: lessons from the quantification of endogenous kinins. Peptides 21: 1903-1940, 2000.
6. Bogaard HJ, Natarajan R, Henderson SC, Long CS, Kraskauskas D, Smithson L, Ockaili R, McCord JM, Voelkel NF. Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation 120: 1951-1960, 2009.
7. Bogaard HJ, Natarajan R, Mizuno S, Abbate A, Chang PJ, Chau VQ, Hoke NN, Kraskauskas D, Kasper M, Salloum FN, Voelkel NF. Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. Am J Respir Crit Care Med 182: 652-660, 2010.
8. Botney MD, Bahadori L, Gold LI. Vascular remodeling in primary pulmonary hypertension. Potential role for transforming growth factorbeta. Am J Pathol 144: 286-295, 1994.
9. Braun MU, Szalai P, Strasser RH, Borst MM. Right ventricular hypertrophy and apoptosis after pulmonary artery banding: regulation of PKC isozymes. Cardiovasc Res 59: 658-667, 2003.
10. Bristow MR, Minobe W, Rasmussen R, Larrabee P, Skerl L, Klein JW, Anderson FL, Murray J, Mestroni L, Karwande SV, et al. Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. J Clin Invest 89: 803-815, 1992.
11. Bristow MR, Zisman LS, Lowes BD, Abraham WT, Badesch DB, Groves BM, Voelkel NF, Lynch DM, Quaife RA. The pressureoverloaded right ventricle in pulmonary hypertension. Chest 114: 101S- 106S, 1998.
12. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med 134: 550-560, 2001.
13. Brown RD, Ambler SK, Li M, Sullivan TM, Henry LN, Crossno JT Jr, Long CS, Garrington TP, Stenmark KR. MAP kinase kinase kinase-2 (MEKK2) regulates hypertrophic remodeling of the right ventricle in hypoxia-induced pulmonary hypertension. Am J Physiol Heart Circ Physiol 304: H269-H281, 2013.
14. Campian ME, Hardziyenka M, de Bruin K, van Eck-Smit BL, de Bakker JM, Verberne HJ, Tan HL. Early inflammatory response during the development of right ventricular heart failure in a rat model. Eur J Heart Fail 12: 653-658, 2010.
15. Campian ME, Verberne HJ, Hardziyenka M, de Bruin K, Selwaness M, van den Hoff MJ, Ruijter JM, van Eck-Smit BL, de Bakker JM, Tan HL. Serial noninvasive assessment of apoptosis during right ventricular disease progression in rats. J Nucl Med 50: 1371-1377, 2009.
16. Chaponnier C, Gabbiani G. Pathological situations characterized by altered actin isoform expression. J Pathol 204: 386-395, 2004.
17. Chatterjee S, Biondi-Zoccai G, Abbate A, D'Ascenzo F, Castagno D, Van Tassell B, Mukherjee D, Lichstein E. Benefits of beta blockers in patients with heart failure and reduced ejection fraction: network metaanalysis. BMJ 346: f55, 2013.
18. Chin KM, Kim NH, Rubin LJ. The right ventricle in pulmonary hypertension. Coron Artery Dis 16: 13-18, 2005.
19. Ciarka A, Doan V, Velez-Roa S, Naeije R, van de Borne P. Prognostic significance of sympathetic nervous system activation in pulmonary arterial hypertension. Am J Respir Crit Care Med 181: 1269-1275, 2010.
20. Clerk A, Sugden PH. Activation of protein kinase cascades in the heart by hypertrophic G protein-coupled receptor agonists. Am J Cardiol 83: 64H-69H, 1999.
21. Coats L, Khambadkone S, Derrick G, Hughes M, Jones R, Mist B, Pellerin D, Marek J, Deanfield JE, Bonhoeffer P, Taylor AM. Physiological consequences of percutaneous pulmonary valve implantation: the different behaviour of volume- and pressure-overloaded ventricles. Eur Heart J 28: 1886-1893, 2007.
22. 2+, calcineurin, and NF-AT. Cell 96: 611-614, 1999.
23. Csiszar A, Labinskyy N, Olson S, Pinto JT, Gupte S, Wu JM, Hu F, Ballabh P, Podlutsky A, Losonczy G, de Cabo R, Mathew R, Wolin MS, Ungvari Z. Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats. Hypertension 54: 668-675, 2009.
24. Davies RJ, Morrell NW. Molecular mechanisms of pulmonary arterial hypertension: role of mutations in the bone morphogenetic protein type II receptor. Chest 134: 1271-1277, 2008.
25. de Groote P, Millaire A, Foucher-Hossein C, Nugue O, Marchandise X, Ducloux G, Lablanche JM. Right ventricular ejection fraction is an independent predictor of survival in patients with moderate heart failure. J Am Coll Cardiol 32: 948-954, 1998.
26. de Man FS, Handoko ML, van Ballegoij JJ, Schalij I, Bogaards SJ, Postmus PE, van der Velden J, Westerhof N, Paulus WJ, Vonk- Noordegraaf A. Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension. Circ Heart Fail 5: 97-105, 2012.
27. de Man FS, Tu L, Handoko ML, Rain S, Ruiter G, Francois C, Schalij I, Dorfmuller P, Simonneau G, Fadel E, Perros F, Boonstra A, Postmus PE, van der Velden J, Vonk-Noordegraaf A, Humbert M, Eddahibi S, Guignabert C. Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension. Am J Respir Crit Care Med 186: 780-789, 2012.
28. de Visser YP, Walther FJ, Laghmani el H, Boersma H, van der Laarse A, Wagenaar GT. Sildenafil attenuates pulmonary inflammation and fibrin deposition, mortality and right ventricular hypertrophy in neonatal hyperoxic lung injury. Respir Res 10: 30, 2009.
29. Dell'Italia LJ. The right ventricle: anatomy, physiology, and clinical importance. Curr Probl Cardiol 16: 653-720, 1991.
30. Desai RV, Guichard JL, Mujib M, Ahmed MI, Feller MA, Fonarow GC, Meyer P, Iskandrian AE, Bogaard HJ, White M, Aban IB, Aronow WS, Deedwania P, Waagstein F, Ahmed A. Reduced right ventricular ejection fraction and increased mortality in chronic systolic heart failure patients receiving beta-blockers: insights from the BEST trial. Int J Cardiol 163: 61-67, 2013.
31. Drake JI, Gomez-Arroyo J, Dumur CI, Kraskauskas D, Natarajan R, Bogaard HJ, Fawcett P, Voelkel NF. Chronic carvedilol treatment partially reverses the right ventricular failure transcriptional profile in experimental pulmonary hypertension. Physiol Genomics 45: 449-461, 2013.
32. Field ME, Solomon SD, Lewis EF, Kramer DB, Baughman KL, Stevenson LW, Tedrow UB. Right ventricular dysfunction and adverse outcome in patients with advanced heart failure. J Card Fail 12: 616- 620, 2006.
33. Fogel MA, Rychik J. Right ventricular function in congenital heart disease: pressure and volume overload lesions. Prog Cardiovasc Dis 40: 343-356, 1998.
34. Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 61: 227-237, 2004.
35. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328: 1732-1739, 1993.
36. Giardini A, Lovato L, Donti A, Formigari R, Gargiulo G, Picchio FM, Fattori R. A pilot study on the effects of carvedilol on right ventricular remodelling and exercise tolerance in patients with systemic right ventricle. Int J Cardiol 114: 241-246, 2007.
37. Goldstein JA, Harada A, Yagi Y, Barzilai B, Cox JL. Hemodynamic importance of systolic ventricular interaction, augmented right atrial contractility and atrioventricular synchrony in acute right ventricular dysfunction. J Am Coll Cardiol 16: 181-189, 1990.
38. Green EM, Givertz MM. Management of acute right ventricular failure in the intensive care unit. Curr Heart Fail Rep 9: 228-235, 2012.
39. Guihaire J, Bogaard HJ, Flecher E, Noly PE, Mercier O, Haddad F, Fadel E. Experimental models of right heart failure: a window for translational research in pulmonary hypertension. Semin Respir Crit Care Med 34: 689-699, 2013.
40. Haddad F, Doyle R, Murphy DJ, Hunt SA. Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure. Circulation 117: 1717- 1731, 2008.
41. Haddad F, Hunt SA, Rosenthal DN, Murphy DJ. Right ventricular function in cardiovascular disease, part I: Anatomy, physiology, aging, and functional assessment of the right ventricle. Circulation 117: 1436- 1448, 2008.
42. Hein S, Arnon E, Kostin S, Schonburg M, Elsasser A, Polyakova V, Bauer EP, Klovekorn WP, Schaper J. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 107: 984-991, 2003.
43. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 7: 589-600, 2006.
44. Hopkins WE. The remarkable right ventricle of patients with Eisenmenger syndrome. Coron Artery Dis 16: 19-25, 2005.
45. Hopkins WE, Ochoa LL, Richardson GW, Trulock EP. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 15: 100-105, 1996.
46. Hopkins WE, Waggoner AD. Severe pulmonary hypertension without right ventricular failure: the unique hearts of patients with Eisenmenger syndrome. Am J Cardiol 89: 34-38, 2002.
47. Howard LS. Prognostic factors in pulmonary arterial hypertension: assessing the course of the disease. Eur Respir Rev 20: 236-242, 2011.
48. Hu H, Sachs F. Stretch-activated ion channels in the heart. J Mol Cell Cardiol 29: 1511-1523, 1997.
49. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43: 13S-24S, 2004.
50. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Cottin V, Degano B, Jais X, Montani D, Souza R, Simonneau G. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 122: 156-163, 2010.
51. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119: e391-e479, 2009.
52. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69: 11-25, 1992.
53. Ikeda S, Hamada M, Hiwada K. Cardiomyocyte apoptosis with enhanced expression of P53 and Bax in right ventricle after pulmonary arterial banding. Life Sci 65: 925-933, 1999.
54. Ikeda S, Satoh K, Kikuchi N, Miyata S, Suzuki K, Omura J, Shimizu T, Kobayashi K, Fukumoto Y, Sakata Y, Shimokawa H. Crucial role of rho-kinase in pressure overload-induced right ventricular hypertrophy and dysfunction in mice. Arterioscler Thromb Vasc Biol 34: 1260-1271, 2014.
55. Iwadate K, Doi M, Tanno K, Katsumura S, Ito H, Sato K, Yonemura I, Ito Y. Right ventricular damage due to pulmonary embolism: examination of the number of infiltrating macrophages. Forensic Sci Int 134: 147-153, 2003.
56. Jasmin JF, Lucas M, Cernacek P, Dupuis J. Effectiveness of a nonselective ET(A/B) and a selective ET(A) antagonist in rats with monocrotaline-induced pulmonary hypertension. Circulation 103: 314- 318, 2001.
57. Kaemmerer H, Mebus S, Schulze-Neick I, Eicken A, Trindade PT, Hager A, Oechslin E, Niwa K, Lang I, Hess J. The adult patient with Eisenmenger syndrome: a medical update after dana point part I: epidemiology, clinical aspects and diagnostic options. Curr Cardiol Rev 6: 343-355, 2010.
58. Katz WE, Gasior TA, Quinlan JJ, Lazar JM, Firestone L, Griffith BP, Gorcsan J 3rd. Immediate effects of lung transplantation on right ventricular morphology and function in patients with variable degrees of pulmonary hypertension. J Am Coll Cardiol 27: 384-391, 1996.
59. Kaya MG, Lam YY, Erer B, Ayhan S, Vatankulu MA, Nurkalem Z, Meric M, Eren M, Eryol NK. Long-term effect of bosentan therapy on cardiac function and symptomatic benefits in adult patients with Eisenmenger syndrome. J Card Fail 18: 379-384, 2012.
60. Kuc RE, Carlebur M, Maguire JJ, Yang P, Long L, Toshner M, Morrell NW, Davenport AP. Modulation of endothelin receptors in the failing right ventricle of the heart and vasculature of the lung in human pulmonary arterial hypertension. Life Sci 118: 391-396, 2014.
61. Kwon DH, Eom GH, Kee HJ, Nam YS, Cho YK, Kim DK, Koo JY, Kim HS, Nam KI, Kim KK, Lee IK, Park SB, Choi HS, Kook H. Estrogen-related receptor gamma induces cardiac hypertrophy by activating GATA4. J Mol Cell Cardiol 65: 88-97, 2013.
62. Lahm T, McCaslin CA, Wozniak TC, Ghumman W, Fadl YY, Obeidat OS, Schwab K, Meldrum DR. Medical and surgical treatment of acute right ventricular failure. J Am Coll Cardiol 56: 1435-1446, 2010.
63. Laser M, Willey CD, Jiang W, Cooper Gt Menick DR, Zile MR, Kuppuswamy D. Integrin activation and focal complex formation in cardiac hypertrophy. J Biol Chem 275: 35624-35630, 2000.
64. Laviades C, Varo N, Fernandez J, Mayor G, Gil MJ, Monreal I, Diez J. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 98: 535-540, 1998.
65. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J 18: 816-827, 2004.
66. Lim JY, Park SJ, Hwang HY, Park EJ, Nam JH, Kim J, Park SI. TGF-beta1 induces cardiac hypertrophic responses via PKC-dependent ATF-2 activation. J Mol Cell Cardiol 39: 627-636, 2005.
67. Lindsey JB, Hillis LD. Clinical update: atrial septal defect in adults. Lancet 369: 1244-1246, 2007.
68. Liu A, Schreier DA, Tian L, Eickhoff JC, Wang Z, Hacker TA, Chesler NC. Direct and indirect protection of right ventricular function by estrogen in an experimental model of pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol 307: H273-H283, 2014.
69. Liu B, Luo XJ, Yang ZB, Zhang JJ, Li TB, Zhang XJ, Ma QL, Zhang GG, Hu CP, Peng J. Inhibition of NOX/VPO1 Pathway and Inflammatory Reaction by Trimethoxystilbene in Prevention of Cardiovascular Remodeling in Hypoxia-induced Pulmonary Hypertensive Rats. J Cardiovasc Pharmacol 63: 567-576, 2014.
70. Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of betaadrenergic signaling in heart failure? Circ Res 93: 896-906, 2003.
71. Lowes BD, Minobe W, Abraham WT, Rizeq MN, Bohlmeyer TJ, Quaife RA, Roden RL, Dutcher DL, Robertson AD, Voelkel NF, Badesch DB, Groves BM, Gilbert EM, Bristow MR. Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest 100: 2315-2324, 1997.
72. Maarman G, Lecour S, Butrous G, Thienemann F, Sliwa K. A comprehensive review: the evolution of animal models in pulmonary hypertension research; are we there yet? Pulm Circ 3: 739-756, 2013.
73. Mak S, Witte KK, Al-Hesayen A, Granton JJ, Parker JD. Cardiac sympathetic activation in patients with pulmonary arterial hypertension. Am J Physiol Regul Integr Comp Physiol 302: R1153-R1157, 2012.
74. McFadden DG, Barbosa AC, Richardson JA, Schneider MD, Srivastava D, Olson EN. The Hand1 and Hand2 transcription factors regulate expansion of the embryonic cardiac ventricles in a gene dosagedependent manner. Development 132: 189-201, 2005.
75. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33: 1787-1847, 2012.
76. McMurtry IF, Bauer NR, Fagan KA, Nagaoka T, Gebb SA, Oka M. Hypoxia and Rho/Rho-kinase signaling. Lung development versus hypoxic pulmonary hypertension. Adv Exp Med Biol 543: 127-137, 2003.
77. Mehta SR, Eikelboom JW, Natarajan MK, Diaz R, Yi C, Gibbons RJ, Yusuf S. Impact of right ventricular involvement on mortality and morbidity in patients with inferior myocardial infarction. J Am Coll Cardiol 37: 37-43, 2001.
78. Meldrum DR, Shames BD, Meng X, Fullerton DA, McIntyre RC Jr, Grover FL, and Harken AH. Nitric oxide downregulates lung macrophage inflammatory cytokine production. Ann Thorac Surg 66: 313-317, 1998.
79. Mendes LA, Dec GW, Picard MH, Palacios IF, Newell J, Davidoff R. Right ventricular dysfunction: an independent predictor of adverse outcome in patients with myocarditis. Am Heart J 128: 301-307, 1994.
80. Minegishi S, Kitahori K, Murakami A, Ono M. Mechanism of pressure- overload right ventricular hypertrophy in infant rabbits. Int Heart J 52: 56-60, 2011.
81. Mitsuno M, Nakano S, Shimazaki Y, Taniguchi K, Kawamoto T, Kobayashi J, Matsuda H, Kawashima Y. Fate of right ventricular hypertrophy in tetralogy of Fallot after corrective surgery. Am J Cardiol 72: 694-698, 1993.
82. Moceri P, Dimopoulos K, Liodakis E, Germanakis I, Kempny A, Diller GP, Swan L, Wort SJ, Marino PS, Gatzoulis MA, Li W. Echocardiographic predictors of outcome in Eisenmenger syndrome. Circulation 126: 1461-1468, 2012.
83. Molkentin JD. Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs. Cardiovasc Res 63: 467-475, 2004.
84. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93: 215-228, 1998.
85. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, Kakishita M, Fukushima K, Okano Y, Nakanishi N, Miyatake K, Kangawa K. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102: 865- 870, 2000.
86. Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A, St Aubin C, Webster L, Rebeyka IM, Ross DB, Light PE, Dyck JR, Michelakis ED. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 116: 238-248, 2007.
87. Nagendran J, Gurtu V, Fu DZ, Dyck JR, Haromy A, Ross DB, Rebeyka IM, Michelakis ED. A dynamic and chamber-specific mitochondrial remodeling in right ventricular hypertrophy can be therapeutically targeted. J Thorac Cardiovasc Surg 136: 168-178, 2008.
88. Nagendran J, Sutendra G, Paterson I, Champion HC, Webster L, Chiu B, Haromy A, Rebeyka IM, Ross DB, Michelakis ED. Endothelin axis is upregulated in human and rat right ventricular hypertrophy. Circ Res 112: 347-354, 2013.
89. Nootens M, Kaufmann E, Rector T, Toher C, Judd D, Francis GS, Rich S. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol 26: 1581-1585, 1995.
90. Park AM, Wong CM, Jelinkova L, Liu L, Nagase H, Suzuki YJ. Pulmonary hypertension-induced GATA4 activation in the right ventricle. Hypertension 56: 1145-1151, 2010.
91. Park HK, Park SJ, Kim CS, Paek YW, Lee JU, Lee WJ. Enhanced gene expression of renin-angiotensin system, TGF-beta1, endothelin-1 and nitric oxide synthase in right-ventricular hypertrophy. Pharmacol Res 43: 265-273, 2001.
92. Pedram A, Razandi M, Narayanan R, Dalton JT, McKinsey TA, Levin ER. Estrogen regulates histone deacetylases to prevent cardiac hypertrophy. Mol Biol Cell 24: 3805-3818, 2013.
93. Phrommintikul A, Tran L, Kompa A, Wang B, Adrahtas A, Cantwell D, Kelly DJ, Krum H. Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction. Am J Physiol Heart Circ Physiol 294: H1804-H1814, 2008.
94. Piotrowicz E, Biernacka EK, Mazgaj M, Fronczak A, Demkow M, Ruzyllo W, Kowalski M, Spiewak M, Hoffman P, Piotrowski W, Piotrowicz R. Electrocardiographic characteristics of the right ventricle following hemodynamic improvement after percutaneous pulmonary valve implantation, one year follow-up. J Electrocardiol 47: 612-617, 2014.
95. Popio KA, Gorlin R, Teichholz LE, Cohn PF, Bechtel D, Herman MV. Abnormalities of left ventricular function and geometry in adults with an atrial septal defect. Ventriculographic, hemodynamic and echocardiographic studies. Am J Cardiol 36: 302-308, 1975.
96. Provencher S, Herve P, Jais X, Lebrec D, Humbert M, Simonneau G, Sitbon O. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 130: 120-126, 2006.
97. Rain S, Handoko ML, Trip P, Gan CT, Westerhof N, Stienen GJ, Paulus WJ, Ottenheijm CA, Marcus JT, Dorfmuller P, Guignabert C, Humbert M, Macdonald P, Dos Remedios C, Postmus PE, Saripalli C, Hidalgo CG, Granzier HL, Vonk-Noordegraaf A, van der Velden J, de Man FS. Right ventricular diastolic impairment in patients with pulmonary arterial hypertension. Circulation 128: 2016- 2025, 2011-2010, 2013.
98. Rain S, Handoko ML, Vonk Noordegraaf A, Bogaard HJ, van der Velden J, de Man FS. Pressure-overload-induced right heart failure. Pflugers Archiv 466: 1055-1063, 2014.
99. Ramahi TM, Longo MD, Cadariu AR, Rohlfs K, Carolan SA, Engle KM, Samady H, Wackers FJ. Left ventricular inotropic reserve and right ventricular function predict increase of left ventricular ejection fraction after beta-blocker therapy in nonischemic cardiomyopathy. J Am Coll Cardiol 37: 818-824, 2001.
100. Ravassa S, Fortuno MA, Gonzalez A, Lopez B, Zalba G, Fortuno A, Diez J. Mechanisms of increased susceptibility to angiotensin II-induced apoptosis in ventricular cardiomyocytes of spontaneously hypertensive rats. Hypertension 36: 1065-1071, 2000.
101. Reddy S, Zhao M, Hu DQ, Fajardo G, Hu S, Ghosh Z, Rajagopalan V, Wu JC, Bernstein D. Dynamic microRNA expression during the transition from right ventricular hypertrophy to failure. Physiol Genomics 44: 562-575, 2012.
102. Ritchie M, Waggoner AD, Davila-Roman VG, Barzilai B, Trulock EP, Eisenberg PR. Echocardiographic characterization of the improvement in right ventricular function in patients with severe pulmonary hypertension after single-lung transplantation. J Am Coll Cardiol 22: 1170-1174, 1993.
103. Roldan V, Marin F, Gimeno JR, Ruiz-Espejo F, Gonzalez J, Feliu E, Garcia-Honrubia A, Saura D, de la Morena G, Valdes M, Vicente V. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. Am Heart J 156: 85-91, 2008.
104. Romeih S, Kroft LJ, Bokenkamp R, Schalij MJ, Grotenhuis H, Hazekamp MG, Groenink M, de Roos A, Blom NA. Delayed improvement of right ventricular diastolic function and regression of right ventricular mass after percutaneous pulmonary valve implantation in patients with congenital heart disease. Am Heart J 158: 40-46, 2009.
105. Rosen LB, Ginty DD, Greenberg ME. Calcium regulation of gene expression. Adv Second Messenger Phosphoprotein Res 30: 225-253, 1995.
106. Rouleau JL, Kapuku G, Pelletier S, Gosselin H, Adam A, Gagnon C, Lambert C, Meloche S. Cardioprotective effects of ramipril and losartan in right ventricular pressure overload in the rabbit: importance of kinins and influence on angiotensin II type 1 receptor signaling pathway. Circulation 104: 939-944, 2001.
107. Ruiter G, Ying Wong Y, de Man FS, Louis Handoko M, Jaspers RT, Postmus PE, Westerhof N, Niessen HW, van der Laarse WJ, Vonk- Noordegraaf A. Right ventricular oxygen supply parameters are decreased in human and experimental pulmonary hypertension. J Heart Lung Transplant 32: 231-240, 2013.
108. Rutledge JM, Nihill MR, Fraser CD, Smith OE, McMahon CJ, Bezold LI. Outcome of 121 patients with congenitally corrected transposition of the great arteries. Pediatr Cardiol 23: 137-145, 2002.
109. Ruwhof C, van der Laarse A. Mechanical stress-induced cardiac hypertrophy: mechanisms and signal transduction pathways. Cardiovasc Res 47: 23-37, 2000.
110. Sadoshima J, Takahashi T, Jahn L, Izumo S. Roles of mechanosensitive ion channels, cytoskeleton, and contractile activity in stretchinduced immediate-early gene expression and hypertrophy of cardiac myocytes. Proc Natl Acad Sci U S A 89: 9905-9909, 1992.
111. Schulman LL, Leibowitz DW, Anandarangam T, DiTullio MR, McGregor CC, Smith CR, Homma S. Variability of right ventricular functional recovery after lung transplantation. Transplantation 62: 622- 625, 1996.
112. Shaddy RE, Boucek MM, Hsu DT, Boucek RJ, Canter CE, Mahony L, Ross RD, Pahl E, Blume ED, Dodd DA, Rosenthal DN, Burr J, LaSalle B, Holubkov R, Lukas MA, Tani LY. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA 298: 1171-1179, 2007.
113. Sharma R, Bolger AP, Li W, Davlouros PA, Volk HD, Poole-Wilson PA, Coats AJ, Gatzoulis MA, Anker SD. Elevated circulating levels of inflammatory cytokines and bacterial endotoxin in adults with congenital heart disease. Am J Cardiol 92: 188-193, 2003.
114. Shyy JY, Chien S. Role of integrins in cellular responses to mechanical stress and adhesion. Curr Opin Cell Biol 9: 707-713, 1997.
115. Skhiri M, Hunt SA, Denault AY, Haddad F. Evidence-based management of right heart failure: a systematic review of an empiric field. Rev Esp Cardiol 63: 451-471, 2010.
116. Srivastava D, Thomas T, Lin Q, Kirby ML, Brown D, Olson EN. Regulation of cardiac mesodermal and neural crest development by the bHLH transcription factor, dHAND. Nat Genet 16: 154-160, 1997.
117. Steiner MK, Syrkina OL, Kolliputi N, Mark EJ, Hales CA, Waxman AB. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res 104: 236-244, 2009.
118. Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res 99: 675-691, 2006.
119. Sutendra G, Dromparis P, Paulin R, Zervopoulos S, Haromy A, Nagendran J, Michelakis ED. A metabolic remodeling in right ventricular hypertrophy is associated with decreased angiogenesis and a transition from a compensated to a decompensated state in pulmonary hypertension. J Mol Med 91: 1315-1327, 2013.
120. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, McMahon G, Waltenberger J, Voelkel NF, Tuder RM. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 15: 427-438, 2001.
121. Tatsukawa Y, Kiyosue T, Arita M. Mechanical stretch increases intracellular calcium concentration in cultured ventricular cells from neonatal rats. Heart Vessels 12: 128-135, 1997.
122. Teiger E, Than VD, Richard L, Wisnewsky C, Tea BS, Gaboury L, Tremblay J, Schwartz K, Hamet P. Apoptosis in pressure overloadinduced heart hypertrophy in the rat. J Clin Invest 97: 2891-2897, 1996.
123. Umar S, Hessel M, Steendijk P, Bax W, Schutte C, Schalij M, van der Wall E, Atsma D, van der Laarse A. Activation of signaling molecules and matrix metalloproteinases in right ventricular myocardium of rats with pulmonary hypertension. Pathol Res Pract 203: 863-872, 2007.
124. Umar S, van der Valk EJ, Schalij MJ, van der Wall EE, Atsma DE, van der Laarse A. Integrin stimulation-induced hypertrophy in neonatal rat cardiomyocytes is NO-dependent. Mol Cell Biochem 320: 75-84, 2009.
125. Urashima T, Zhao M, Wagner R, Fajardo G, Farahani S, Quertermous T, Bernstein D. Molecular and physiological characterization of RV remodeling in a murine model of pulmonary stenosis. Am J Physiol Heart Circ Physiol 295: H1351-H1368, 2008.
126. van de Veerdonk MC, Kind T, Marcus JT, Mauritz GJ, Heymans MW, Bogaard HJ, Boonstra A, Marques KM, Westerhof N, Vonk- Noordegraaf A. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol 58: 2511-2519, 2011.
127. van der Bom T, Winter MM, Bouma BJ, Groenink M, Vliegen HW, Pieper PG, van Dijk AP, Sieswerda GT, Roos-Hesselink JW, Zwinderman AH, Mulder BJ. Effect of valsartan on systemic right ventricular function: a double-blind, randomized, placebo-controlled pilot trial. Circulation 127: 322-330, 2013.
128. van Straten A, Vliegen HW, Lamb HJ, Roes SD, van der Wall EE, Hazekamp MG, de Roos A. Time course of diastolic and systolic function improvement after pulmonary valve replacement in adult patients with tetralogy of Fallot. J Am Coll Cardiol 46: 1559-1564, 2005.
129. Velez-Roa S, Ciarka A, Najem B, Vachiery JL, Naeije R, van de Borne P. Increased sympathetic nerve activity in pulmonary artery hypertension. Circulation 110: 1308-1312, 2004.
130. Voelkel NF, Quaife RA, Leinwand LA, Barst RJ, McGoon MD, Meldrum DR, Dupuis J, Long CS, Rubin LJ, Smart FW, Suzuki YJ, Gladwin M, Denholm EM, Gail DB. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 114: 1883-1891, 2006.
131. von Haehling S, von Bardeleben RS, Kramm T, Thiermann Y, Niethammer M, Doehner W, Anker SD, Munzel T, Mayer E, Genth- Zotz S. Inflammation in right ventricular dysfunction due to thromboembolic pulmonary hypertension. Int J Cardiol 144: 206-211, 2010.
132. Vonk Noordegraaf A, Galie N. The role of the right ventricle in pulmonary arterial hypertension. Eur Respir Rev 20: 243-253, 2011.
133. Vonk-Noordegraaf A, Haddad F, Chin KM, Forfia PR, Kawut SM, Lumens J, Naeije R, Newman J, Oudiz RJ, Provencher S, Torbicki A, Voelkel NF, Hassoun PM. Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology. J Am Coll Cardiol 62: D22-D33, 2013.
134. Watts JA, Marchick MR, Kline JA. Right ventricular heart failure from pulmonary embolism: key distinctions from chronic pulmonary hypertension. J Card Fail 16: 250-259, 2010.
135. Watts JA, Zagorski J, Gellar MA, Stevinson BG, Kline JA. Cardiac inflammation contributes to right ventricular dysfunction following experimental pulmonary embolism in rats. J Mol Cell Cardiol 41: 296-307, 2006.
136. 2+ signaling in cardiac myocyte excitation-transcription coupling. J Clin Invest 116: 675-682, 2006.
137. Xie YP, Chen B, Sanders P, Guo A, Li Y, Zimmerman K, Wang LC, Weiss RM, Grumbach IM, Anderson ME, Song LS. Sildenafil prevents and reverses transverse-tubule remodeling and Ca(2+) handling dysfunction in right ventricle failure induced by pulmonary artery hypertension. Hypertension 59: 355-362, 2012.
138. Xu DQ, Luo Y, Liu Y, Wang J, Zhang B, Xu M, Wang YX, Dong HY, Dong MQ, Zhao PT, Niu W, Liu ML, Gao YQ, Li ZC. Beta-estradiol attenuates hypoxic pulmonary hypertension by stabilizing the expression of p27kip1 in rats. Respir Res 11: 182, 2010.
139. Yap LB, Ashrafian H, Mukerjee D, Coghlan JG, Timms PM. The natriuretic peptides and their role in disorders of right heart dysfunction and pulmonary hypertension. Clin Biochem 37: 847-856, 2004.
140. Yap LB, Mukerjee D, Timms PM, Ashrafian H, Coghlan JG. Natriuretic peptides, respiratory disease, and the right heart. Chest 126: 1330-1336, 2004.
141. Zaffran S, Kelly RG, Meilhac SM, Buckingham ME, Brown NA. Right ventricular myocardium derives from the anterior heart field. Circ Res 95: 261-268, 2004.
142. Zhang L, Pu Z, Wang J, Zhang Z, Hu D. Baicalin inhibits hypoxiainduced pulmonary artery smooth muscle cell proliferation via the AKT/HIF-1alpha/p27-associated pathway. Int J Mol Sci 15: 8153-8168, 2014.
143. Zhang Y, Dai L, Wu S, Chen P, Zhao S. Atorvastatin attenuates involvement of RhoA/Rho-kinase pathway and NF-kappaB activation in hypoxic pulmonary hypertensive rats. Chin Med J 127: 869-872, 2014.
144. Zhang Y, Wang X, Xu X, Wang J, Liu X, Chen Y. Distinct microRNA expression signatures in human right atrial and ventricular myocardium. Mol Cell Biochem 371: 23-29, 2012.
145. Zou Y, Akazawa H, Qin Y, Sano M, Takano H, Minamino T, Makita N, Iwanaga K, Zhu W, Kudoh S, Toko H, Tamura K, Kihara M, Nagai T, Fukamizu A, Umemura S, Iiri T, Fujita T, Komuro I. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol 6: 499-506, 2004.
146. Zuo XR, Wang Q, Cao Q, Yu YZ, Wang H, Bi LQ, Xie WP. Nicorandil prevents right ventricular remodeling by inhibiting apoptosis and lowering pressure overload in rats with pulmonary arterial hypertension. PloS One 7: e44485, 2012.